Spruce Biosciences Inc Ordinary Shares SPRB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Spruce Biosciences to Participate in the Craig-Hallum Biotech Catalyst Conference
-
Spruce Biosciences Announces Presentation of MPS IIIB Natural History Data at the 55th Child Neurology Society Annual Meeting
-
Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
-
Spruce Biosciences Announces Launch of MPS3BStudy.com
-
Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026
-
Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
-
Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences
-
Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development
Trading Information
- Previous Close Price
- $41.47
- Day Range
- $39.21–41.84
- 52-Week Range
- $38.06–159.41
- Bid/Ask
- $39.30 / $49.00
- Shares Outstanding
- 2.87M
- Market Cap
- $113.95M
- Volume/Avg
- 88,433 / 78,567
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 8
Valuation
|
Metric
|
SPRB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.33 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
SPRB
|
|---|---|
Quick Ratio | 8.78 |
Current Ratio | 9.23 |
Interest Coverage | −28.29 |
Quick Ratio
SPRB
Profitability
|
Metric
|
SPRB
|
|---|---|
Return on Assets (Normalized) | −88.48% |
Return on Equity (Normalized) | −122.84% |
Return on Invested Capital (Normalized) | −109.87% |
Return on Assets
SPRB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|n?^$>#% | LOCK|j!y&s | $127B | |||
| Moderna Inc
MRNA
| LOCK|<q#%$n# | LOCK|T> | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|c@dXc?v | LOCK|bc#@ | $81B | |||
| argenx SE ADR
ARGX
| LOCK|sv&&?^# | LOCK|w> | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|$L>sF% | LOCK|?q | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|LF?fJ%q | LOCK|Jrz& | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|j#!dtFm | LOCK|F!M? | $27B | |||
| Incyte Corp
INCY
| LOCK|p>fX>h | LOCK|<m | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|lDG^pB | LOCK|Bw! | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|>ZN@?Q | LOCK|LJ | $14B |
United States